Given Verastem's (VSTM) depressing price movement since reaching $10 in 2019 and AVEO's volatile start to 2019, neither company has brought forth any interesting data for presentation at ASCO 2019. Here in part one, I will briefly summarize the data Verastme intends to present in the coming days, and then in part two, I will discuss AVEO's data . . .
About Chris Stang
As a young investor, I focus developing biotech companies. I focus strongly on fundamentals, digging deeper to understand the financial and regulatory position of companies. The biotechnology sector is very volatile, please use caution and do your own additional due diligence before investing. I also secondarily focus on small security and defense companies that provide long-term growth opportunities.